Figure 2.
Figure 2. Cumulative incidence of relapse-related mortality and non-relapse mortality for FM- versus FAI-conditioned patients. / Abbreviations: FM, fludarabine, melphalan; FAI, fludarabine, cytarabine, idarubicin. / This figure was originally published in Blood. de Lima M, Anagnostopoulos A, Munsell M, et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004;104:865–872 © the American Society of Hematology. Used with permission.

Cumulative incidence of relapse-related mortality and non-relapse mortality for FM- versus FAI-conditioned patients.

Abbreviations: FM, fludarabine, melphalan; FAI, fludarabine, cytarabine, idarubicin.

This figure was originally published in Blood.

de Lima M, Anagnostopoulos A, Munsell M, et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004;104:865–872
© the American Society of Hematology. Used with permission.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal